The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer
Abstract
CONTEXT: Randomized trials of short-term aspirin use for prevention of recurrent colorectal adenoma have provided compelling evidence of a causal relationship between aspirin and colorectal neoplasia. However, data on long-term risk of colorectal cancer according to dose, timing, or duration of therapy with aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) remain limited. OBJECTIVE: To examine the influence of aspirin and NSAIDs in prevention of colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort study of 82 911 women enrolled in the Nurses' Health Study providing data on medication use biennially since 1980 and followed up through June 1, 2000. MAIN OUTCOME MEASURE: Incident colorectal cancer. RESULTS: Over a 20-year period, we documented 962 cases of colorectal cancer. Among women who regularly used aspirin (> or =2 standard [325-mg] tablets per week), the multivariate relative risk (RR) for colorectal cancer was 0.77 (95% confidence interval [CI], 0.67-0.88) compared with nonregular users. However, significant risk reduction was not observed until more than 10 years of use (P< or =.001 for trend). The benefit appeared related to dose: compared with women who reported no use, the multivariate RRs for cancer were 1.10 (95% CI, 0.92-1.31) for women who used 0.5 to 1.5 standard aspirin tablets per week, 0.89 (95% CI, 0.73-1.10) for 2 to 5 aspirin per week, 0.78 (95% CI, 0.62-0.97) for 6 to 14 aspirin per week, and 0.68 (95% CI, 0.49-0.95) for more than 14 aspirin per week (P<.001 for trend). Notably, women who used more than 14 aspirin per week for longer than 10 years in the past had a multivariate RR for cancer of 0.47 (95% CI, 0.31-0.71). A similar dose-response relationship was found for nonaspirin NSAIDs (P = .007 for trend). The incidence of reported major gastrointestinal bleeding events per 1000 person-years also appeared to be dose-related: 0.77 among women who denied any aspirin use; 1.07 for 0.5 to 1.5 standard aspirin tablets per week; 1.07 for 2 to 5 aspirin per week; 1.40 for 6 to 14 aspirin per week; and 1.57 for more than 14 aspirin per week. CONCLUSIONS: Regular, long-term aspirin use reduces risk of colorectal cancer. Nonaspirin NSAIDs appear to have a similar effect. However, a significant benefit of aspirin is not apparent until more than a decade of use, with maximal risk reduction at doses greater than 14 tablets per week. These results suggest that optimal chemoprevention for colorectal cancer requires long-term use of aspirin doses substantially higher than those recommended for prevention of cardiovascular disease, but the dose-related risk of gastrointestinal bleeding must also be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reproducibility and validity of a semiquantitative food frequency questionnaire
WILLETT, W. C., SAMPSON, L., STAMPFER, M. J., ROSNER, B., BAIN, C., WITSCHI, J., HENNEKENS, C. H., & SPEIZER, F. E. (1985) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114086 · Cited by 4,274
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90246-1 · Cited by 2,514
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Inhibition of NF-κB by Sodium Salicylate and Aspirin
Kopp, E., & Ghosh, S. (1994) · Science · doi:10.1126/science.8052854 · Cited by 1,753
Aspirin Use and Reduced Risk of Fatal Colon Cancer
Thun, M. J., Namboodiri, M. M., & Heath, C. W. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112053252301 · Cited by 1,673
Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging
O'Connell, J. B., Maggard, M. A., & Ko, C. Y. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh275 · Cited by 1,599
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Cited by
Wolf, A. M. D., Fontham, E. T. H., Church, T. R., Flowers, C. R., Guerra, C. E., LaMonte, S. J., Etzioni, R., McKenna, M. T., Oeffinger, K. C., Shih, Y. T., et al. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21457 · Cited by 1,944
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Algra, A. M., & Rothwell, P. M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70112-2 · Cited by 831
Flossmann, E., & Rothwell, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60747-8 · Cited by 820
Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2
Chan, A. T., Ogino, S., & Fuchs, C. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067208 · Cited by 781
Self-citationMeta-analyses of colorectal cancer risk factors
Johnson, C. M., Wei, C., Ensor, J. E., Smolenski, D. J., Amos, C. I., Levin, B., & Berry, D. A. (2013) · Cancer Causes & Control · doi:10.1007/s10552-013-0201-5 · Cited by 779
Primary Prevention of Colorectal Cancer
Chan, A. T., & Giovannucci, E. L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.057 · Cited by 723
Self-citationCuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., Jankowski, J., La Vecchia, C., Meyskens, F., Senn, H. J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70035-x · Cited by 714
Aspirin Use and Survival After Diagnosis of Colorectal Cancer
Chan, A. T. (2009) · JAMA · doi:10.1001/jama.2009.1112 · Cited by 557
Self-citationNon-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
Ulrich, C. M., Bigler, J., & Potter, J. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1801 · Cited by 548
Ogino, S., Chan, A. T., Fuchs, C. S., & Giovannucci, E. (2011) · Gut · doi:10.1136/gut.2010.217182 · Cited by 522
Self-citationAspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials
Cole, B. F., Logan, R. F., Halabi, S., Benamouzig, R., Sandler, R. S., Grainge, M. J., Chaussade, S., & Baron, J. A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn485 · Cited by 476
Aspirin and Folic Acid for the Prevention of Recurrent Colorectal Adenomas
Logan, R. F. A., Grainge, M. J., Shepherd, V. C., Armitage, N. C., & Muir, K. R. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.10.014 · Cited by 398
Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer
Cao, Y., Nishihara, R., Wu, K., Wang, M., Ogino, S., Willett, W. C., Spiegelman, D., Fuchs, C. S., Giovannucci, E. L., & Chan, A. T. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.6396 · Cited by 369
Self-citationLee, Y.-C., Chen, T. H.-H., Chiu, H.-M., Shun, C.-T., Chiang, H., Liu, T.-Y., Wu, M.-S., & Lin, J.-T. (2013) · Gut · doi:10.1136/gutjnl-2012-302240 · Cited by 349
Rostom, A., Dubé, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00010 · Cited by 343
Dubé, C., Rostom, A., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00009 · Cited by 334
Harris, R. E. (2009) · Inflammopharmacology · doi:10.1007/s10787-009-8049-8 · Cited by 329
Epidemiology of Colorectal Cancer
Keum, N., & Giovannucci, E. L. (2017) · Pathology and Epidemiology of Cancer · doi:10.1007/978-3-319-35153-7_21 · Cited by 329
Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., & Fuchs, C. S. (2006) · Circulation · doi:10.1161/circulationaha.105.595793 · Cited by 319
Self-citationPlatelets and cancer: a casual or causal relationship: revisited
Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9498-0 · Cited by 316
Trends in the use of aspirin and nonsteroidal anti‐inflammatory drugs in the general U.S. population
Zhou, Y., Boudreau, D. M., & Freedman, A. N. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3463 · Cited by 304
Aspirin and cancer risk: a quantitative review to 2011
Bosetti, C., Rosato, V., Gallus, S., Cuzick, J., & La Vecchia, C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds113 · Cited by 297
Notch post-translationally regulates β-catenin protein in stem and progenitor cells
Kwon, C., Cheng, P., King, I. N., Andersen, P., Shenje, L., Nigam, V., & Srivastava, D. (2011) · Nature Cell Biology · doi:10.1038/ncb2313 · Cited by 284
Effect of aspirin and NSAIDs on risk and survival from colorectal cancer
Din, F. V. N., Theodoratou, E., Farrington, S. M., Tenesa, A., Barnetson, R. A., Cetnarskyj, R., Stark, L., Porteous, M. E., Campbell, H., & Dunlop, M. G. (2010) · Gut · doi:10.1136/gut.2009.203000 · Cited by 284
Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview
Chan, A. T., Arber, N., Burn, J., Chia, W. K., Elwood, P., Hull, M. A., Logan, R. F., Rothwell, P. M., Schrör, K., & Baron, J. A. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0391 · Cited by 276
Self-citationAnanthakrishnan, A. N., Higuchi, L. M., Huang, E. S., Khalili, H., Richter, J. M., Fuchs, C. S., & Chan, A. T. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-5-201203060-00007 · Cited by 262
Self-citationThe Role of Inflammation in Colon Cancer
Janakiram, N. B., & Rao, C. V. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-0348-0837-8_2 · Cited by 151
Proton Pump Inhibitor Use and Risk of Colorectal Cancer: A Population-Based, Case–Control Study
Robertson, D. J., Larsson, H., Friis, S., Pedersen, L., Baron, J. A., & Sørensen, H. T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.06.014 · Cited by 139
Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases
Panigrahy, D., Gartung, A., Yang, J., Yang, H., Gilligan, M. M., Sulciner, M. L., Bhasin, S. S., Bielenberg, D. R., Chang, J., Schmidt, B. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127282 · Cited by 132
Metadata
- Authors
- Chan, A. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-08-24
- Volume
- 294
- Issue
- 8
- Pages
- 914
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2127989833
- Cited by
- 478
- References
- 71
- FWCI
- 18.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.